SOURCE-LINKED STUDY SUMMARY
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.
Abstract summarizedQuality not appraised
- What was studied
- Discovery research assessed LY3437943, later known as retatrutide, a peptide activating glucagon, GIP and GLP-1 receptors, through laboratory experiments, obese-mouse studies and an early phase 1 single-dose study.
- Who / model studied
- The abstract describes obese mice and a phase 1 study but does not report sample sizes, participant characteristics or comparators.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- In mice, treatment reduced weight and improved glucose control, with increased energy expenditure and reduced calorie intake. In phase 1, weight reduction persisted to day 43 after one dose; the reported safety and tolerability profile resembled other incretins.
- Limitations & context
- Authors called for further clinical assessment. The mouse mechanism does not establish the same mechanism or effectiveness in humans; the abstract provides no detailed adverse-event counts.
Read summary source ↗ · Prepared 9/22/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1016/j.cmet.2022.07.013